FDA Hears Mixed Message On Feasibility, Need For Orkambi Vs. Kalydeco Trial
Executive Summary
Some experts say a study in CF patients with the 508del mutation could not pass IRB muster, but others see an opportunity to answer the question of whether two drugs are needed or one will suffice.
You may also be interested in...
A Busy Year-End, In Brief: December Brings Slate Of Approvals, And Setbacks
In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.